SREBP1在宫颈癌发生发展中的作用研究
The role of SREBP1 in the oncogenesis and development of cervical cancer.
目的 探讨固醇调节元件结合蛋白（SREBP1）在宫颈癌中的表达及其在宫颈癌发生发展中的作用及意义。方法 宫颈标本共100例，采自2009年1月至2013年12月郑州人民医院妇科，包括宫颈癌组织50例，同期病理检查的宫颈非癌组织50例作为对照。采用实时定量聚合酶链反应（RT-PCR）检测宫颈癌组织及正常宫颈组织中SREBP1 mRNA的表达。分析SREBP1的表达水平与宫颈癌标本的病理分级、临床分期等临床资料的相关性。结果 SREBP1 mRNA在宫颈癌中的表达高于正常宫颈组织（0.60±0.18对0.13±0.04，P＜0.01）。SREBP1的表达在宫颈癌中与病理分级、临床分期有相关性（P＜0.05），与病人年龄、肿瘤大小及肿瘤分型无关（P＞0.05）。SREBP1调控内源性脂肪酸合成酶（FASN）表达，两者呈正相关关系（r = 0.705，P＜0.05）。结论 SREBP1参与宫颈癌的发生发展，为寻找宫颈癌临床治疗的潜在靶点提供了一定的思路。
Abstract： Objective To research the expressions of SREBP1 in cervical cancer and explore the significances of SREBP1 in oncogenesis and development of cervical cance. Methods A total of 100 cervical samples were collected from Department of Gynaecology, Zhengzhou People's Hospital (from Jan. 2010 to Jan. 2015), including 50 cervical cancer tissues and 50 cervical noncancer tissues of the same donor as controls. The expression of SREBP1 in cervical cancer tissues and in the paired cervical noncancer tissues was evaluated by RT-PC. Its correlation with the clinicopathological parameters including tumor grade and stage was subjected to statistical analysis.Results RT-PCR showed that SREBP1 mRNA levels were significantly increased in cervical tumors（0.60±0.18 vs. 0.13±0.04，P<0.01）. Additionally， the expression levels of SREBP1 mRNA were correlated with clinical stages and tumor grade significantly（P<0.05），however,there was no correlation of SREBP1 expression with the patient’s age， tumor size and tumor type. In cervical cancer group，there was a positive correlation between SREBP1 mRNA expression and FASN mRNA expression （r=0.705，P<0.05）. Conclusion SREBP1 may play an important role in oncogenesis and development of cervical cancer，which may become new potential targets for clinical treatment of cervical cancer.
宫颈癌 / 固醇调节元件结合蛋白-l / 脂肪酸合成酶
cervical cancer / sterol regulatory element binding protein1 / fatty acid synthase
［1］ Jemal A，Bray F，Center MM，et al. Global cancer statistics［J］. CA，2011，61：69-90.
［2］ Fang J，Zhang H，Jin S. Epigenetics and cervical cancer：from pathogenesis to therapy［J］. Tumour Biol，2014， 35（6）：5083-5093.
［3］ Deberardinis RJ，Sayed N，Ditsworth D，et al. Brick by brick：metabolism and tumor cell growth［J］. Curr Opin Genet Develop，2008，18（1）：54-61.
［4］ Swinnen JV，Brusselmans K，Verhoeven G. Increased lipogenesis in cancer cells：new players，novel targets［J］. Curr Opin Clin Nutr Metab Care，2006，9（4）：358-365.
［5］ Menendez JA，Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis［J］. Nat Rev Cancer，2007，7（10）：763-777.
［6］ Ren S，Li X，Rodriguez-Agudo D，et al. Sulfated oxysterol，25HC3S，is a potent regulator of lipid metabolism in human hepatocytes［J］. Biochem Biophys Res Commun，2007，360（4）：802-808.
［7］ Li W，Tai Y，Zhou J，et al. Repression of endometrial tumor growth by targeting SREBPl and lipogenesis［J］. Cell Cycle 2012，11（12）：2348-2358.
［8］ Yamashita T，Honda M，Takatori H，et al. Activation of lipogenic pathway correlates with cell proliferation and poor prognosis in hepatocellular carcinoma［J］. J Hepatol，2009，50（1）：100-110.
［9］ Fimita E，Pai SK，Zhan R，et al. Fatty acid synthase gene is up-regulated by hypoxia via activation of Akt and sterol regulatory element binding protein-1［J］. Cancer Res，2008，68（4）：1003-1011.
［10］ Migita T，Ruiz S，Fornari A，et al. Fatty acid synthase：a metabolic enzyme and candidate oncogene in prostate cancer［J］. J Natl Cancer Inst，2009，101（7）：519-532.
［11］ Jung SY，Jeon HK，Choi JS，et al． Reduced expression of FASN through SREBP-1 down-regulation is responsible for hypoxic cell death in HepG2 cell［J］. J Cell Biochem，2012，113（12）：3730-3739．
［12］ Vazquez-Martin A，Colomer R，Brunet J，et al. Overexpression of fatty acid synthase gene activates HERl /HER2 tyrosine kinase receptors in human breast epithelial cells［J］. Cell Prolif，2008，41（1）：59-85．
［13］ Menendez JA，Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis［J］. Nat Rev Cancer，2007，7（10）：763-777．
［14］ Lupu R，Menendez JA. Targeting fatty acid synthase in breast and endometrial cancer：an alternative to selective estrogen receptor modulators?［J］. Endocrinology，2006，147（9）：4056-4066.
［15］ Eberhard Y，Gronda M，Hurren R，et al. Inhibition of SREBP1 sensitizes cells to death ligands［J］. Oncotarget，2011，2（3）：186-196.
［16］ Yamashita T，Honda M，Takatori H，et al. Activation of lipogenic pathway correlates with cell proliferation and poor prognosis in hepatocellular carcinoma［J］. J Hepatol，2009，50（1）：100-110.
［17］ Li JN，Mahmoud MA，Han WF，et al. Sterol regulatory element-binding protein-1 participates in the regulation of fatty acid synthase expression in colorectal neoplasia［J］. Experim Cell Res，2000，261（1）：159-165.
［18］ Rahaman MT，Nakayama K，Ishikawa M，et al. Fatty acid synthase is a potential therapeutic target in estrogen receptor-/progesterone receptor-positive endometrioid endometrial cancer［J］. Oncology，2013，84（3）：166-173．
［19］ DeAngelis T，Wu K，Pestell R，et al． The type 1 insulin-like growth factor receptor and resistance to DACH1［J］.Cell Cycle，2011，10（12）：1956-1959．
［20］ Lee MY，Moon JS，Park SW，et al. KLF5 enhances SREBP-1 action in androgen-dependent induction of fatty acid synthase in prostate cancer cells［J］.Biochem J，2009，417（1）：313-322.
（2015-02-04收稿 2015-04-05修回）
/
| 〈 |
|
〉 |
